Kory Blackwell
Family Medicine · Hattiesburg, MSNPI 1255751525
Payments from drug & device makers
Across 314 payments — averaging $15.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Takeda Pharmaceuticals U.S.A., Inc.$552
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$320
- Novo Nordisk$294
- Amgen$229
- Boehringer Ingelheim$224
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,715100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 103 | $1,216 |
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $552 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $320 |
| Novo Nordisk | 22 | $294 |
| Amgen | 16 | $229 |
| Boehringer Ingelheim | 14 | $224 |
| Otsuka America Pharmaceutical, Inc. | 10 | $209 |
| Pfizer | 12 | $202 |
| Corium, LLC | 12 | $196 |
| Biohaven Pharmaceutical Holding Company Ltd. | 12 | $193 |
| Lilly USA, LLC | 12 | $183 |
| Merck | 8 | $152 |
| Idorsia Pharmaceuticals US Inc | 6 | $96 |
| Biohaven Pharmaceuticals, Inc. | 5 | $83 |
| Abbott | 4 | $72 |
| Johnson & Johnson | 4 | $64 |
| Axsome Therapeutics, Inc. | 3 | $62 |
| GSK | 4 | $57 |
| Astellas Pharma US Inc | 3 | $40 |
| Tris Pharma Inc | 2 | $34 |
| AstraZeneca | 2 | $33 |
| Shield Therapeutics Inc | 2 | $33 |
| IBSA Pharma Inc. | 2 | $28 |
| Bausch Health US, LLC | 2 | $28 |
| Medtronic | 1 | $20 |
| Novartis | 1 | $20 |
| Dexcom, Inc. | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $13 |
| Adlon Therapeutics L.p. | 1 | $12 |
How this compares
$4,715 in reported general payments places this provider in the 80th percentile of 971 family medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 69 | $92,430 |
| JardianceEmpagliflozin | 85 | $71,406 |
| EliquisApixaban | 38 | $48,792 |
| MounjaroTirzepatide | 28 | $38,923 |
| JanuviaSitagliptin Phosphate | 51 | $37,881 |
| LinzessLinaclotide | 44 | $29,177 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $23,934 |
| XareltoRivaroxaban | 13 | $22,913 |
| FarxigaDapagliflozin Propanediol | 13 | $21,814 |
| MyrbetriqMirabegron | 20 | $18,457 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 11 | $9,646 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $6,179 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $6,166 |
| MovantikNaloxegol Oxalate | 15 | $5,739 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 54 | $5,020 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $294 | $92,43069 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $224 | $81,05396 claims |
| PfizerEliquis | $202 | $48,79238 claims |
| Lilly USA, LLCMounjaro | $183 | $38,92328 claims |
| MerckJanuvia | $152 | $37,88151 claims |
| AbbVieLinzess, Synthroid | $1,216 | $31,73789 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $57 | $30,11343 claims |
| AstraZenecaFarxiga, Bevespi Aerosphere | $33 | $26,28124 claims |
| Johnson & JohnsonXarelto | $64 | $22,91313 claims |
| Astellas Pharma US IncMyrbetriq | $40 | $18,45720 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $13 | $898158 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 971 family medicine providers in Mississippi.
Other family medicine in Hattiesburg
- Rambod RouhbakhshHattiesburg$6M
- Omolara OtaigbeHattiesburg$17K
- Deborah CopelandHattiesburg$13K
- J DumasHattiesburg$12K
- Anny EvansHattiesburg$10K
- Paul MatherneGulfport$14.4M
- Timothy QuinnRidgeland$8M
- Sean KerbyGulfport$6.6M
- Randall HulingOlive Branch$4.6M
- Demetri MarshallPort Gibson$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.